Our compounds disrupt the metabolic and inflammatory triggers in both cancer and quasi-cancerous cells in the tumor microenvironment. By impacting multiple cell types, we are enabling effective, lasting cancer treatments. Our vision is that we’ll be able to disrupt the pharma industry the way fintech has disrupted banking.
Location: United States, California, San Francisco
Investors 3
| Date | Name | Website |
| 26.03.2022 | Y Combinat... | ycombinato... |
| 25.05.2022 | MBC BioLab... | mbcbiolabs... |
| - | StartX | startx.com |